(October 28, 2004) -- Boston Scientific Corporation (NYSE:BSX) today announced that it has launched a full line of mid-urethral sling products for the treatment of female stress urinary incontinence. These products, which have been introduced by the Company's Urology and Gynecology businesses over the last several months, provide alternative approaches for the placement of mid-urethral slings. A sling is a medical device that provides support on the pelvic floor to help a woman maintain urinary continence and avoid unintended leakage.

Boston Scientific's three new products are:

Advantage™ System:

Designed for the placement of mid-urethral slings via transvaginal delivery. This approach is used by many gynecologists and urogynecologists.

Lynx™ System:

Designed for the placement of mid-urethral slings supra-pubically (from the abdomen downward). This approach is used by many urologists.

Obtryx™ System:

Designed for the placement of mid-urethral slings via the transobturator approach (laterally through the pelvis). This approach is gaining popularity among urologists, urogynecologists and gynecologists.

Each of these products uses the "Advantage™ Mesh" sling, which is appropriate for all three types of mid-urethral sling procedures, regardless of the physician's delivery choice.

"The early feedback on these products has been very positive," said John Pedersen, President of Boston Scientific's Urology and Gynecology businesses. "With the recent launch of the Obtryx system for the transobturator delivery of our mid-urethral sling, we continue to broaden our product offering in this fast-growing market. With three distinct delivery approaches for the placement of slings, we are well positioned to continue meeting the needs of the different physician specialists who use these devices."

The market for mid-urethral sling products is currently estimated to be $130 million annually.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.

This press release contains forward-looking statements. The Company wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with litigation, clinical trials, the regulatory approval process, reimbursement policies, commercialization of new technologies, intellectual property, and other factors described in the Company's filings with the Securities and Exchange Commission.